Although the disease known as temporal arteritis, giant cell arteritis, and Horton’s disease has been known since at least the 10th century, Hutchinson (1890) and Horton (1932) characterized the condition in the more recent medical literature. The diagnosis of this potentially serious illness can be surprisingly elusive, and treatment is fraught with some frustrating pitfalls. For the most part, careful evaluation of patients (usually elderly) with the typical presentation of head pain and constitutional signs yields prompt diagnosis. Treatment with corticosteroids, the standard since the mid-1950s, is usually very successful in relieving pain and tenderness and in preventing visual and other sequelae. This article discusses the evolution of medical understanding of the disease, pathophysiology, diagnosis, and modern treatment options.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
References and Recommended Reading
Horton BT, Magath TB, Brown GE: An undescribed form of arteritis of temporal vessels. Mayo Clin Proc 1932, 7:700–701.
Meadows SP: Temporal or giant cell arteritis. Proc Royal Soc Med 1966, 59:329–333.
Ainsworth RW, Gresham GA, Balmforth GV: Pathological changes in temporal arteries removed from unselected cadavers. J Clin Pathol 1961, 14:115–119.
Paulley JW, Hughes JP: Giant cell arteritis or arteritis of the aged. BMJ 1960, 2:1562–1567.
Hutchinson J: On a peculiar form of thrombotic arteritis of the aged which is sometimes productive of gangrene. Arch Surg 1890, 1:323–329.
Jennings GH: Arteritis of the temporal arteries. Lancet 1938, 1:424–428.
Wolff HG: Headache and Other Head Pain. New York: Oxford University Press; 1948.
Mohan N, Kerr G: Spectrum of giant cell vasculitis. Curr Rheumatol Rep 2000, 2:390–395. Thorough but concise description of the pathogenesis of GCA that offers clues to its diagnosis and management. The concept of steroid resistance also is covered.
Petursdottir V, Johansson H, Nordborg E, Nordborg C: The epidemiology of biopsy-positive giant cell arteritis: special reference to cyclic fluctuations. Rheumatology 1999, 38:1208–1212.
AbuRrahma AF, Thaxton L: Temporal arteritis: diagnostic and therapeutic considerations. Am Surg 1996, 62:449–451.
Ward TN, Levin M, Wong RL: Headache caused by giant cell arteritis. Curr Treat Options Neurol 2004, 6:499–505.
Smetana GW, Shmerling RH: Does this patient have temporal arteritis? JAMA 2002, 287:92–101. This is a very clinically relevant, evidence-based article that deals with the decision-making involved in the evaluation and management of patients with GCA.
Huston KA, Hunder GG, Lie JT, et al.: Temporal arteritis. a 25-year epidemiologic, clinical, and pathologic study. Ann Int Med 1978, 88:162–167.
Guttenberg SA, Emery RW, Milobsky SA, Geballa M: Cranial arteritis mimicking odontogenic pain: report of case. J Am Dent Assoc 1989, 119:621–623.
Caselli RJ, Hunder GG, Whisnant JP: Neurologic disease in biopsy-proven giant cell (temporal) arteritis. Neurology 1988, 38:352–359.
Classification Committee of the International Headache Society: International Classification of Headache Disorders II. Cephalalgia 2004, 24(suppl 1):68–69.
Redillas C, Solomon S: Recent advances in temporal arteritis. Curr Headache Rep 2003, 2:119–124. This is a very complete review article, with an emphasis on the clinical features of GCA.
Ward TN: Headache in cerebrovascular disease. In Office Practice of Neurology. Edited by Samuels MA, Feske S. New York: Churchill Livingstone; 1996:1144.
Jundt JW, Mock D: Temporal arteritis with normal erythrocyte sedimentation rate presenting as occipital neuralgia. Arthritis Rheum 1991, 34:217–219.
Pfadenhauer K, Weber H: Giant cell arteritis of the occipital arteries: a prospective color-coded duplex sonography study in 78 patients. J Neurol 2003, 250:844–849.
Barilla-LaBarca ML, Lenschow DJ, Brasington RD: Polymyalgia rheumatica/temporal arteritis: recent advances. Curr Rheumatol Rep 2002, 4:39–46. Outstanding review article that covers clinical, basic science, and therapeutic aspects of GCA.
Gold R, Fontana A, Zierz S: Therapy of neurological disorders in systemic vasculitis. Semin Neurol 2003, 23:207–214. A clinically useful and comprehensive review article about the management of vasculitis.
Ray-Chadhuri N, Kine DA, Tijani SO, et al.: Effect of prior steroid treatment on temporal artery biopsy findings in giant cell arteritis. Br J Ophthal 2002, 86:530–532.
Nordborg E, Nordborg C: Giant cell arteritis: strategies in diagnosis and treatment. Curr Opin Rheumatol 2004, 16:25–30.
Hayreh SS, Zimmerman B: Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy. Ophthalmology 2003, 110:1204–1215.
Wilke WS, Hoffman GS: Treatment of corticosteroid-resistant giant cell arteritis. Rheum Dis Clin North Am 1995, 21:59–71.
Hoffman GS: Treatment of giant-cell arteritis: where we have been and why we must move on. Cleve Clin J Med 2002, 69(suppl 2):SII117-SII20.
Krall PL, Mazanec DJ, Wilke WS: Methotrexate for corticosteroidresistant polymyalgia rheumatica and giant cell arteritis. Cleve Clin J Med 1986, 56:253–257.
Demaziere A: Dapsone in the long-term treatment of temporal arteritis [Letter]. JAMA 1989, 87:3.
De Vita S, Tavoni A, Jeracitano G, et al.: Treatment of giant cell arteritis with cyclophophamide pulses [Letter]. J Int Med 1992, 232:373–375.
Weyand CM, Kaiser M, Yang H, et al.: Therapeutic effects of acetylsalicylic acid in giant cell arteritis. Arthritis Rheum 2002, 46:457–466.
Nesher G, Berkun Y, Mates M, et al.: Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum 2004, 50:1332–1337.
Airo P, Antonioli CM, Vianelli M, Toniati P: Anti-tumour necrosis factor treatment with infliximab in a case of giant cell arteritis resistant to steroid and immunosuppressive drugs [Letter]. Rheumatology 2002, 41:347–349.
Tan AL, Holdsworth J, Pease C, et al.: Successful treatment of resistant giant cell arteritis with etanercept. Ann Rheum Dis 2003, 62:373–374.
Andonopoulos AP, Meimaris N, Daoussis D, et al.: Experience with infliximab (anti-TNF alpha monoclonal antibody) as monotherapy for giant cell arteritis. Ann Rheum Dis 2002, 62:1116.
Physician’s Desk Reference, edn 58. Montvale, NJ: Thomson PDR; 2004.
Both M, Jahnke T, Reinhold-Keller E, et al.: Percutaneous management of occlusive arterial disease associated with vasculitis: a single center experience. Cardiovasc Intervent Radiol 2003, 26:19–26.
Amann-Vesti BR, Koppensteiner R, Rainoni L, et al.: Immediate- and long-term outcome of upper extremity balloon angioplasty in giant cell arteritis. J Endovasc Ther 2003, 10:371–375.
Rights and permissions
About this article
Cite this article
Levin, M., Ward, T.N. Horton’s disease: Past and present. Current Science Inc 9, 259–263 (2005). https://doi.org/10.1007/s11916-005-0033-4
- Cluster Headache
- Giant Cell Arteritis
- Temporal Artery
- Temporal Arteritis